VMD-928 100 mg Tablet for carcinoma, adenoid cystic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Jun 2018: Trial started, NCT03556228
  2. 14 Jun 2018: Trial registered, NCT03556228

The trials

NCT03556228: VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

State
Under way
Phase
Phase 1 and Phase 2
People
242 planned
Started
8 Jun 2018
Primary completion
Dec 2027
Arms
VMD-928 monotherapy
Results
None posted
  1. 8 Jun 2018: Trial started
  2. 14 Jun 2018: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.